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Aim: The aim of this study was to assess the frequency and characteristics of complications
in patients on anticoagulant therapy who were to undergo invasive procedure.
Methods and Results: We sent a questionnaire to 2758 doctors who were on the mailing list
of the Japanese Society of Cardiac Pacing and Electrophysiology in August 2004. We
received 614 questionnaires (response rate, 22.3%). Out of the 614 doctors, 19 (3.1%)
reported that their patients had embolic events upon the interruption of warfarin therapy
during dental extraction. In patients undergoing invasive procedures such as surgery,
endoscopy, pacemaker implantation, and catheterization, 168 (27.4%) of the 614 doctors
reported embolic events after the interruption of warfarin therapy. Further, 255 (41.5%) of the
614 doctors reported bleeding episodes when warfarin therapy was continued during the
invasive procedures.
Conclusion: Several complications of diﬀerent types were reported to occur in patients
receiving warfarin therapy who underwent elective invasive procedures, regardless of whether
warfarin administration was interrupted or continued at the time of the invasive procedure.
Therefore, it is necessary to make careful decisions about the management of patients on
warfarin therapy who will be undergoing invasive procedures.
(J Arrhythmia 2010; 26: 96–102)
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Introductions
Many doctors encounter a diﬃcult situation when
they have to perform elective procedure or minor
surgery on patients receiving warfarin-sodium ther-
apy. Cessation of anticoagulant therapy in the
perioperative period may expose the patients to
increased risk of thromboembolic events, while
continuing anticoagulant therapy may increase the
risk of bleeding. There are limited guidelines or
randomized controlled trials that provide informa-
tion about perioperative management of patients on
warfarin therapy. The aim of this study was to assess
the frequency and characteristics of complications in
patients receiving anticoagulant therapy who were to
undergo invasive procedures.
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Methods
We sent a questionnaire to 2758 doctors who were
on the mailing list of the Japanese Society of Cardiac
Pacing and Electrophysiology (JASPE) in August
2004. The doctors were instructed to return com-
pleted questionnaires anonymously in an enclosed
stamped addressed envelope. Through the question-
naire, we collected information about the interna-
tional normalized ratios (INR) of the pathological
conditions (valvular disease, atrial ﬁbrillation (AF),
and cerebral infarction), the characteristics of pa-
tients on warfarin therapy, including patient respons-
es to dental extraction, surgery, endoscopy, pace-
maker implantation, and catheterization, and the
adverse eﬀects of warfarin use.
Results
We received 614 questionnaires (response rate,
22.3%) from 277 doctors aged in their 50s (45.1%),
162 (26.4%) in 40s, and 132 (21.5%) in 60s. The
number of patients prescribed with warfarin per
month was <10 (23.5%), 10–20 (16.9%), and 20–30
(15.3%). Further, 93.3%, 92.8%, and 82.4% of
doctors prescribed warfarin to patients with AF,
patients who had undergone replacement of heart
valves, and patients with cerebrovascular disease,
respectively.
Dental extraction
For patients who underwent dental extraction,
17.1% of doctors administered the same dosage or
decreased the dose of warfarin continuously, and
75.7% of doctors interrupted warfarin therapy during
the extraction procedure (Figure 1). Among doctors
who administered the same or a decreased dose of
warfarin, 29.5%, 30.9%, and 13.8% reported INR
values in the range of 1.0–1.3, 1.3–1.5, and 1.5–2.0,
respectively. Out of the 614 doctors, 19 (3.1%)
reported that their patients had embolic events when
warfarin therapy was interrupted. Among the 19
embolic events, 13 were brain infarction, 4 were
myocardial infarction, and 2 were vascular occlusion
of the extremities (Figure 2). No bleeding episodes
were reported in patients for whom warfarin therapy
was continued.
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Figure 1 Technique for the management of patients on
warfarin who were to undergo dental extraction.
Warfarin administration was continued by 17.1% of doctors and
discontinued by 75.7% in patients who were to undergo dental
extraction.
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Figure 2 Thrombosis in dental extraction
Out of the 614 doctors, 19 (3.1%) reported that their patients had an
embolic event due to discontinuation of warfarin therapy. Among
these patients, 13, 4, and 2 developed brain infarction, myocardial
infarction, and vascular occlusion of the extremities, respectively.
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Invasive procedures
The reasons for interruption of warfarin therapy
were surgery (92.5%), endoscopy (78.7%), pace-
maker implantation (66.6%), and catheterization
(33.4%). Among the 614 doctors, 168 (27.4%)
reported that their patients had embolic events when
warfarin therapy was interrupted. The types of
embolic events were 161 cerebral infarctions, 41
vascular occlusions of the extremities, 9 pulmonary
infarctions, 3 myocardial infarctions, and 15 others
(Figure 3-A). Among the patients who developed
cerebral infarctions, 90% had PT-INR values of
<1:5 at the time of the event. In patients for whom
warfarin therapy was continued, 255 (41.5%) of the
614 doctors reported bleeding episodes. Among the
614 doctors, 251 (40.9%) reported subcutaneous
bleedings, 28 (4.6%) reported cerebral hemorrhage,
and 21 (3.4%) reported intraperitoneal hemorrhage
(Figure 3-B). Fifty percent of patients with cerebral
hemorrhage had PT-INR values of >2:5 at the time
of the event.
Pacemaker implantation
When treating patients with atrial ﬁbrillation,
23.0% doctors continued warfarin therapy and
62.4% discontinued the therapy (other, 6.0%, no
answer, 8.6%) during pacemaker implantation.
When treating patients with valvular diseases,
31.1% doctors continued warfarin therapy and
51.7% discontinued the therapy (other, 8.2%, no
answer, 9.0%) during pacemaker implantation. Fur-
ther, 35.7% and 51.5% of doctors discontinued
warfarin therapy and performed heparin exchange in
patients with atrial ﬁbrillation and valvular diseases,
respectively, during pacemaker implantation.
Catheterization
In patients with atrial ﬁbrillation, 40.0% of doctors
continued warfarin therapy and 41.5% discontinued
the therapy during catheterization. In patients with
valvular disease, 46.9% of doctors continued war-
farin therapy and 32.4% discontinued the therapy
during catheterization. Further, 40.3% and 54.5% of
doctors performed heparin exchange after interrupt-
ing warfarin administration during catheterization in
patients who received treatment for atrial ﬁbrillation
and valvular diseases, respectively.
Radiofrequency ablation of pulmonary vein
Of the 614 doctors, 135 (22%) reported that they
performed radiofrequency ablation for pulmonary
vein (RFPV). Among these 135 doctors, 78 (57.7%)
and 46 (34.1%) administered warfarin before and
after RFPV, respectively. Further, 52 (38.5%) doc-
tors continued to administer warfarin during RFPV
and 77 (57.0%) discontinued warfarin administration
during the procedure (Figure 4-A). Among doctors
who administered the same or decreased dosage of
warfarin, 59.6% and 28.8% reported PT-INR values
in the range of 1.5–2.0 and 2.0–2.5, respectively, in
patients for whom warfarin was continued during
RFPV (Figure 4-B). Among doctors who discontin-
ued warfarin during RFPV, 67.3% performed hep-
arin exchange and 31.1% did not perform the
exchange (Figure 5). Further, 36.5% and 28.5% of
doctors administered warfarin for 3 and 6 months to
patients who developed paroxysmal atrial ﬁbrillation
after RFPV, respectively, and 82.5% administered
permanent warfarin therapy to patients who devel-
oped persistent or permanent atrial ﬁbrillation after
RFPV (Figure 6).
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Figure 3
A) Thrombosis in invasive procedures
Out of the 614 doctors, 168 (27.4%) reported that their patients
had embolic events due to warfarin discontinuation in invasive
procedures. The types of embolic events were 161 cerebral
infarctions, 41 vascular occlusions of the extremities, 3 myocar-
dial infarctions, and 9 pulmonary infarctions.
B) Bleeding in invasive procedures
Out of the 614 doctors, 255 (41.5%) reported episodes of bleeding
due to warfarin continuation; 251 (40.9%) were subcutaneous
bleeds, 28 (4.6%) were cerebral hemorrhages, and 21 (3.4%) were
intraperitoneal hemorrhages.
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Discussion
Since we administered questionnaires to doctors
who prescribed warfarin, the number of embolic or
bleeding events reported in this study does not reﬂect
the actual number of patients who experienced
thromboembolism or bleeding at the time of the
elective invasive procedure. However, it was note-
worthy that approximately one-third of the doctors
who prescribed warfarin reported that their patients
who underwent invasive procedures experienced
these problems. The incidence of thromboembolism
or bleeding determined in this study may be higher
than that reported in previous papers1) because we
used the questionnaire method to collect the data.
Dental extraction
Several studies have addressed the issue of
management of patients on anticoagulants who need
dental extractions2–5) and various protocols have
been suggested. One approach is to replace warfarin
with heparin before dental extraction, and resume
warfarin administration after the procedure.6) This
method requires hospitalization and careful monitor-
ing of anticoagulation, however, because warfarin
reaches the therapeutic level after several days, the
patients are at a risk of developing postoperative
thromboembolism.7) The second approach is to stop
anticoagulant treatment 2–3 days before dental
extraction, and this method has been widely applied
to manage patients on warfarin therapy. Although
this approach has an advantage of low risk of
hemorrhage, the risk of thromboembolism is high.
The third approach involves continuation of anti-
coagulant treatment. This approach does not appear
to increase postoperative bleeding and it is not
associated with thromboembolism. Many guidelines
have recommended this approach;7–10) however, it
has not yet become a standard procedure. We found
that for patients on warfarin therapy who undergo
dental extractions, only 17.1% of doctors prescribed
the same or a decreased dosage of warfarin, whereas
the majority (75.7%) of doctors instructed the
patients to discontinue warfarin. Further, 19 (3.1%)
of 614 doctors reported that their patients had
embolic events due to warfarin discontinuation.
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A) Warfarin prescription during RFPV
Out of 135 patients, 78 (57.7%) were prescribed warfarin before
and 46 (34.1%) after RFPV. During RFPV, warfarin therapy was
continued in 52 (38.5%) and discontinued in 77 (57.0%) patients.
B) PT-INR of patients who were prescribed continuation of
warfarin therapy during RFPV.
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Figure 5 Discontinuation of warfarin therapy during RFPV
Heparin exchange was performed by 67.3% of doctors and was not
performed by 31.1% in patients in whom warfarin therapy was
discontinued during RFPV.
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According to the Japanese Circulation Society
Guidelines (2004), the continuation of warfarin
around the time of dental extraction was recom-
mended for patients of class IIa. However, we found
that more than 80% of doctors interrupted warfarin
at the time of dental extraction. Adherence to the
guidelines was generally poor for dental procedures.
Invasive procedures
We found that most doctors recommended the
interruption of warfarin therapy for patients under-
going surgery (92.5%), endoscopy (78.7%), pace-
maker implantation (66.6%), and catheterization
(33.4%). Out of the 614 doctors, 168 (27.4%)
reported that patients who underwent invasive
procedures had embolic events on warfarin discon-
tinuation. Cerebral infarction was the most frequent
type of embolic event, and 90% of patients had a PT-
INR value of <1:5 when the embolic event occurred.
Further, 41.5% of doctors reported bleeding episodes
when warfarin therapy was continued. However,
they reported that the incidence of cerebral hemor-
rhage was lower than that of cerebral infarction, and
50% of patients had PT-INR values of >2:5 when
cerebral hemorrhage occurred. For patients at a high
risk for thromboembolism, many experts recom-
mend the bridging therapy. This therapy involves
warfarin discontinuation and maintenance of heparin
dose for therapeutic anticoagulation before the
procedure; pausing heparin administration during
the operation; and resuming heparin treatment after
the procedure until the INR reaches to a desired
therapeutic level. However, there is limited data
which the doctors can use to identify patients who
are at a suﬃciently high risk of thromboembolism
and to weigh the risk of heparin treatment before-
hand.11)
Chaudari12) reported low frequency of acute
gastrointestinal hemorrhage associated with endo-
scopic procedures in patients who received warfarin
treatment. Kumada13) reported a high incidence of
cerebral infarction after warfarin discontinuation
before undergoing endoscopic procedures. The
Guidelines of the Japan Gastroenterological Endos-
copy Society regarding anticoagulation and antipla-
telet therapy indicate that warfarin should be
discontinued 3–4 days before endoscopic procedures
and that the PT-INR at this time should be <1:5.
Heparin infusions are therefore required for high-risk
patients.14)
The number of patients undergoing device im-
plantation and taking warfarin is increasing steadily.
The guidelines recommend bridging therapy for such
patients.8) However, several papers reported that
hematoma was prevalent in patients receiving bridg-
ing therapy.15,16) Further, it has been reported that it
is possible to implant a pacemaker in patients on
warfarin therapy without the interruption of warfarin
therapy.17) In this study, we found that approx-
imately one-third of the doctors continued warfarin
therapy throughout the perioperative periods of
pacemaker implantation. This value is similar to
that reported by Krahn,18) but higher than that
reported by de Bono.19) This approach is supported
by a number of case studies that report a very low
incidence of complications in patients with an INR
>1:5 who undergo implantation.20,21) Hence, pace-
maker implantation can be considered safe even
when continuing oral anticoagulation therapy by
experienced doctors.
There is growing evidence that uninterrupted
warfarin therapy is safe for certain procedures such
as dental extraction and pacemaker implantation.
In addition, cardiac catheterization may not require
interruption of warfarin therapy. Although 33% of
doctors discontinue warfarin at cauterization, there
are no evidence-based guidelines that provide in-
formation about perioperative anticoagulation prac-
tices in such patients.22)
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Figure 6 Warfarin dosing period after RFPV
After RFPV, 36.5% and 28.5% of doctors administered warfarin
therapy for 3 and 6 months to patients who developed paroxysmal
atrial ﬁbrillation, respectively, and 82.5% of them administered
uninterrupted warfarin therapy to patients who developed persis-
tent or permanent atrial ﬁbrillation.
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RFPV is an eﬀective treatment for drug-refractory
atrial ﬁbrillation. The risk of thromboembolic events
at the time of RFPV is a matter of concern, and it is
important to achieve periprocedural anticoagulation
to prevent these complications. However, anticoa-
gulation may increase the risk of bleeding and
hemorrhagic complications in the periprocedural
period. The best anticoagulation procedure is not
known. Most centers discontinue warfarin at least
3–5 days before ablation and apply the bridging
strategy to warfarin therapy after ablation.23–25)
These strategies are consistent with the recommen-
dations made by the 2007 HRS/EHRA/ECAS
expert consensus statement on catheter and surgical
ablation of atrial ﬁbrillation.26)
Study Limitations
This study has several limitations. Firstly, we
administered the questionnaire to doctors who
prescribed warfarin. Therefore, the number of
embolic or bleeding events in this paper does not
reﬂect the actual number of patients who had
thromboembolism or bleeding. Secondly, the present
guidelines are diﬀerent from those formulated at the
time when the questionnaire was administered.
Further, we did not test the speciﬁc hypothesis in
this study. The main purpose was to understand the
eﬀects of warfarin usage during invasive procedures
in patients at risk of thromboembolism.
Conclusion
Several complications of diﬀerent types occurred
in patients on warfarin therapy who underwent
invasive procedures, regardless of whether warfarin
was interrupted or continued during the invasive
procedure. Therefore, it is necessary to make careful
decisions about the management of patients on
warfarin therapy who are required to undergo
invasive procedures.
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